Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Basic Policies for Animal Studies Approved: Korosho
May 29, 2006
- GL for Uterine Corpus Cancer to Be Issued this Autumn
May 29, 2006
- Kissei: Pharma Segment Posts Declines in Sales, Profits
May 29, 2006
- REGULATORY NEWS IN BRIEF
May 29, 2006
- Mr Shoda Lays Out Reorganization Plan: Daiichi Sankyo
May 29, 2006
- Nippon Shinyaku: Mild Pollen Season Hits Sales, Profits
May 29, 2006
- JGPMA Business Plan Outlined by President Yoshida
May 29, 2006
- Pfizer to Launch Detrusitol for OAB in June
May 29, 2006
- Torii: Declines in Sales and Profits
May 29, 2006
- JGPMA to Propose "Drug Benefit Standard Prices System"
May 29, 2006
- Banyu to Re-launch Nu-lotan
May 29, 2006
- ASKA: Higher Cost Ratio Results in Profit Slump
May 29, 2006
- GENERIC NEWS IN BRIEF
May 29, 2006
- Combined Sales, Profits of Top 10 Companies Up in FY2005
May 29, 2006
- Toyama Chemical: Pharma Div. Sales Down 8.4%
May 29, 2006
- Metabolic Syndrome Estimated to Affect 9.4 Mil. Japanese Over 40
May 29, 2006
- Astellas: Stronger Sales, Profits Driven by Overseas Growth
May 29, 2006
- Seikagaku Corp.: Good US Sales Prop Up Business
May 29, 2006
- Eisai: Another Year of Record Sales and Profits
May 29, 2006
- Kirin: Pharma Division Posts 14.5% Growth in Sales
May 29, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…